Mauna Kea Technologies (ALMKT.PA) Osake Kurssi
Mauna Kea Technologies Kurssi
Viimeisten 17 vuoden aikana Mauna Kea Technologiesn liikevaihto kasvoi 3,9 % vuodessa ja ylsi 8,22 M EUR:een. Mauna Kea Technologiesn nettomarginaali 131,0 % on noussut verrattuna −174,6 %:iin muutama vuosi sitten.
Mauna Kea Technologies osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Mauna Kea Technologies liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Mauna Kea Technologies -osakkeesta
The business model of Mauna Kea Technologies SAS revolves around pioneering and delivering innovative endomicroscopy solutions. As a global medical device company, Mauna Kea specializes in developing and commercializing probe-based Confocal Laser Endomicroscopy (pCLE) technology. This enables real-time visualization of tissue at the cellular level during minimally invasive procedures. By combining advanced imaging capabilities with their Cellvizio platform, Mauna Kea enables medical professionals to improve patient care and treatment outcomes. Through strategic partnerships and commercialization efforts, the company aims to leverage its cutting-edge technologies to enhance diagnostic procedures and revolutionize healthcare practices worldwide.
Mauna Kea Technologies SAS is primarily active in the medical industry, specifically in the field of innovative medical devices.
The main competitors of Mauna Kea Technologies SAS in the market include companies such as Intuitive Surgical, Medtronic, Olympus Corporation, and Pentax Medical.
Mauna Kea Technologies SAS is a renowned medical technology company specializing in the development and commercialization of innovative optical biopsy products. Founded in 2000, the company has focused on revolutionizing the detection and treatment of cancer and other diseases through its proprietary Cellvizio® platform. Mauna Kea Technologies has successfully integrated high-resolution imaging and miniaturized endomicroscopy into its advanced devices, enabling physicians to perform real-time, in vivo microscopy during standard procedures. With a commitment to improving patient outcomes and advancing medical knowledge, Mauna Kea Technologies SAS continues to drive advancements in optical biopsy technology worldwide. Find out more about Mauna Kea Technologies SAS on our stock website.
Mauna Kea Technologies SAS has achieved several significant milestones throughout its history. The company introduced Cellvizio, a breakthrough endomicroscopy platform, which has transformed the way physicians diagnose and monitor diseases. The technology has gained widespread recognition and has been adopted by renowned medical institutions globally. Furthermore, Mauna Kea Technologies SAS secured regulatory approvals for its innovative products, strengthening its market position and expanding its customer base. The company's dedication to research and development has led to numerous patents and advancements in optical biopsy solutions. Overall, Mauna Kea Technologies SAS has consistently demonstrated its commitment to advancing medical imaging and improving patient care.
Mauna Kea Technologies SAS is primarily present in several countries and regions globally. It has a significant presence in the United States, particularly in the New York City metropolitan area. In addition, the company operates extensively in Europe, with a strong presence in France, Germany, Italy, Spain, and the United Kingdom. Mauna Kea Technologies SAS also has a growing market share in the Asia-Pacific region, including Australia, China, Japan, and South Korea. With its widespread international presence, Mauna Kea Technologies SAS continues to expand its reach and impact in the field of medical technology and innovative imaging solutions.
Mauna Kea Technologies SAS represents a set of core values and a corporate philosophy that is deeply rooted in innovation, excellence, and patient-centricity. The company strives to revolutionize medical imaging and diagnostics by developing cutting-edge medical devices and technology solutions. Mauna Kea Technologies SAS is committed to improving patient outcomes by providing physicians with real-time, high-resolution imaging capabilities for a more accurate and precise diagnosis. The company also prioritizes ethical practices, sustainable development, and collaboration with healthcare professionals to advance the field of medical imaging. Mauna Kea Technologies SAS is dedicated to pushing boundaries and constantly striving for excellence in the healthcare industry.
9 analyytikkoa arvioi tällä hetkellä Mauna Kea Technologies-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Mauna Kea Technologies-yhtiöltä 7,75 M EUR liikevaihtoa ja −0,01 EUR osakekohtaista tulosta.
Mauna Kea Technologies-osake (ALMKT.PA) on listattuna 6 pörssissä, muun muassa: London (0P5I.L), Frankfurt (1MK.F), München (1MK.MU), Paris (MKEA.PA).
Mauna Kea Technologies SAS is a French company that specializes in the development and marketing of medical devices and procedures that provide precise diagnostic and therapeutic solutions for various types of cancer. The company uses its patented technologies to develop applications for endoscopic imaging, fluorescence microscopy, and optical biopsy.
odotettu liikevaihto Mauna Kea Technologies on 7,75 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Mauna Kea Technologies on −1,75 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Mauna Kea Technologies:n hinta-voitto-suhde (P/E) on tällä hetkellä −9,27. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Mauna Kea Technologies-osakkeen arvostusta.
Mauna Kea Technologies:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,09. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Mauna Kea Technologies-osakkeen arvostuskennuslukuna.
Mauna Kea Technologies:n Eulpool-laatuscore on 1/10.
Mauna Kea Technologies:n ISIN on FR0010609263. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Mauna Kea Technologies:n WKN on A1JCLA. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Mauna Kea Technologies:n ticker on ALMKT.PA. Tämä pörssinoteeraus käytetään Mauna Kea Technologies-osakkeiden kauppaan pörssissä.
Mauna Kea Technologies osake
Mauna Kea Technologies vertaisryhmä
Mauna Kea Technologies Ticker
Mauna Kea Technologies FIGI
Kaikki tunnusluvut ja syvällinen analyysi Mauna Kea Technologies:sta
Meidän osakeanalyysimme Mauna Kea Technologies-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Mauna Kea Technologies:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: